Foghorn Therapeutics Inc. (FHTX) Operating Margin
- Operating margin · 12 months: Value -198.04%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -198.04% | Operating income / revenue. Period ending 2026-06-30. $-72.76M ÷ $36.74M × 100 ≈ -198.04% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -72.76M USD | Operating Income (Loss) |
| Revenue | 36.74M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 78.83M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-72.76M | $36.74M | (m) | $78.83M | (m) | -198.04% |
| 2026-03-31 | $-85.05M | $28.22M | (m) | $82.10M | (m) | -301.34% |
| 2025-12-31 | $-86.39M | $30.91M | (m) | $85.47M | (m) | -279.49% |
| 2025-09-30 | $-86.52M | $24.52M | (m) | $83.93M | (m) | -352.87% |
| 2025-06-30 | $-91.87M | $24.17M | (m) | $88.61M | (m) | -380.04% |
| 2025-03-31 | $-97.40M | $23.50M | (m) | $90.62M | (m) | -414.41% |
| 2024-12-31 | $-102.68M | $22.60M | (m) | $94.53M | (m) | -454.31% |
| 2024-09-30 | $-104.14M | $25.52M | (m) | $98.22M | (m) | -408.14% |
| 2024-06-30 | $-97.36M | $35.19M | (m) | $99.79M | (m) | -276.72% |
| 2024-03-31 | $-102.78M | $33.90M | (m) | $105.24M | (m) | -303.23% |
| 2023-12-31 | $-107.91M | $34.16M | (m) | $109.69M | (m) | -315.93% |
| 2023-09-30 | $-114.33M | $32.57M | (m) | $113.69M | (m) | -351.04% |
| 2023-06-30 | $-125.51M | $21.73M | (m) | $114.37M | (m) | -577.70% |
| 2023-03-31 | $-122.65M | $20.62M | (m) | $111.09M | (m) | -594.90% |
| 2022-12-31 | $-117.14M | $19.23M | (m) | $105.62M | (m) | -609.20% |
| 2022-09-30 | $-113.33M | $15.76M | (m) | $99.87M | (m) | -719.25% |
| 2022-06-30 | $-111.33M | $9.16M | (m) | $93.44M | (m) | -1214.92% |
| 2022-03-31 | $-105.41M | $4.95M | (m) | $86.11M | (m) | -2128.16% |
| 2021-12-31 | $-100.73M | $1.32M | (m) | $80.33M | (m) | -7637.15% |
| 2021-09-30 | $-93.43M | $857.00K | (m) | $74.33M | (m) | -10902.10% |
| 2021-06-30 | $-85.66M | $995.00K | (m) | $69.95M | (m) | -8608.94% |
| 2021-03-31 | $-77.94M | $716.00K | (m) | $64.94M | (m) | -10885.06% |
| 2020-12-31 | $-68.53M | $430.00K | (m) | $57.72M | (m) | -15937.44% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-51.08M | (m) | (m) | $44.36M | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |